Extratumoral Insulin-Like Growth Factor-1 Promotes Resistance To HER2-Targeted Tyrosine Kinase Inhibitors And Macrophage Polarization Through Redox Signaling

Breast cancer that tests positive for a protein called HER2 has become much more treatable in recent years. Doctors use powerful drugs known as tyrosine kinase inhibitors to block the signals that tell these cancer cells to grow and divide. These medicines work well at first, shrinking tumors and saving lives. However, a stubborn problem remains: the cancer often finds a way to survive the treatment and eventually returns. For decades, scientists believed this resistance happened because the cancer cells themselves changed, perhaps by mutating or finding a new internal way to grow. But this view might be missing a crucial part of the story. It turns out that cancer does not exist in a vacuum; it is surrounded by a neighborhood of healthy cells, including immune cells and structural fibers that support the tissue. This surrounding environment, known as the tumor microenvironment, might be doing more than just watching; it could be actively helping the cancer fight back.

A new study from researchers at Shiv Nadar University in India suggests that the key to this survival lies in a hidden conversation between the cancer cells and their neighbors. The researchers focused on a specific type of breast cancer and discovered that when doctors attack the tumor with standard drugs, the cancer cells get stressed. This stress creates a buildup of harmful molecules called reactive oxygen species, which are like rust inside the cell, damaging its DNA and machinery. Normally, this damage would kill the cancer. Instead, the cancer cells send out a silent distress signal that wakes up the surrounding healthy tissue. The neighbors, specifically a type of cell called a fibroblast, respond by pumping out a protective substance called insulin-like growth factor-1. This substance acts as a shield, helping the cancer cells clean up the rust and survive the attack.

The researchers, led by Neha Dutta, set out to understand exactly how this rescue mission works. They started by looking at genetic data from patients who had taken a drug called lapatinib. They found that the cancer cells that survived the treatment were not growing faster; they were actually in a state of hibernation, having stopped dividing to focus entirely on survival. In this dormant state, the cells showed a heavy reliance on a specific survival pathway involving a protein called NRF2, which acts as a master switch for the cell's antioxidant defenses. The team then used computer analysis of thousands of patient samples and single-cell genetic maps to trace the source of the protective signal. They found that the cancer cells themselves were not making the protective substance. Instead, the signal was coming almost entirely from the fibroblasts in the tumor's neighborhood. This confirmed that the resistance was not a solo act by the cancer, but a cooperative effort with the surrounding tissue.

To prove this connection, the scientists moved from computer data to the laboratory bench. They grew breast cancer cells in dishes and treated them with the drugs lapatinib and tucatinib. As expected, the drugs caused the cells to produce high levels of damaging oxidative stress, leading to cell death. However, when the researchers added the protective substance from the fibroblasts, the cancer cells survived. They then tested what would happen if they blocked the cancer cells' ability to receive this signal. When they prevented the cancer cells from detecting the protective substance, the drugs killed them just as they were supposed to. This showed that the cancer's survival depended entirely on this external help.

The study went deeper to map the internal machinery the cancer cells used to accept this help. They found that the protective signal triggered a chain reaction inside the cancer cell. It turned on a pathway involving a protein called PI3K, which then silenced another protein called FOXO. This silencing allowed a third protein, NRF2, to move into the cell's control center and turn on genes that neutralize the damaging rust. The researchers confirmed this by blocking each step of this chain; when they stopped the PI3K protein or removed the NRF2 protein, the cancer cells lost their ability to survive the treatment, even when the protective signal was present. This revealed a precise biological mechanism: the cancer cells hijack a normal repair system used by healthy tissue to protect themselves from the drug's effects.

Perhaps the most surprising discovery was that this survival strategy also changed the behavior of the immune system. The tumor is usually surrounded by immune cells called macrophages, which act as the body's security guards, hunting down and eating cancer cells. The researchers found that the drugs initially made these guards more aggressive, pushing them to attack the tumor. However, the protective signal from the fibroblasts changed the guards' minds. It reprogrammed them to become passive and even helpful to the cancer, a state known as M2 polarization. These reprogrammed guards stopped attacking and instead created an environment that helped the tumor hide. The researchers showed that if they blocked the protective signal, the immune guards remained aggressive and successfully cleared the cancer cells. This meant the cancer was using the same signal to both repair its own internal damage and disarm its external enemies.

To ensure these findings were not just a laboratory trick, the team looked at human tissue samples from patients who had been treated with these drugs. They found that the tumors that remained after treatment showed high levels of the protective signal and the specific genetic markers for the survival pathway they had identified. They also saw that these tumors were filled with the passive, helpful immune cells. This confirmed that the process they observed in the lab was happening in real patients. The study also tested whether this survival mechanism created a weakness. They found that while the cancer cells became very good at handling the oxidative stress caused by the standard drugs, they became vulnerable to a different kind of attack. When the researchers used a higher dose of a drug that blocks multiple growth signals at once, the cancer cells could not cope and died. This suggests that the very adaptation that saves the cancer might make it fragile in a different way.

The implications of this work are significant for how doctors might treat breast cancer in the future. Currently, the focus is almost entirely on attacking the cancer cell directly. This study suggests that doctors might need to treat the cancer's neighborhood as well. By blocking the protective signal from the fibroblasts or stopping the cancer cells from using it, it might be possible to prevent the cancer from developing resistance in the first place. The researchers propose that combining the standard drugs with treatments that block this specific survival pathway could lead to more durable cures. However, they also note that because this pathway is used by healthy cells to protect themselves from stress, blocking it could have side effects. The study does not claim to have a new cure ready for the clinic, but it provides a clear map of a new enemy: the tumor's own support network.

In the end, this research changes the way we think about cancer resistance. It is not just a story of a cancer cell evolving on its own; it is a story of a cancer cell recruiting its neighbors to help it survive. The cancer cells do not fight the drug alone; they call in the fibroblasts to clean up the damage and convince the immune system to stand down. By understanding this collaboration, scientists can begin to design treatments that cut the lines of communication between the cancer and its environment. The goal is to leave the cancer isolated and vulnerable, unable to hide in the safety of its own neighborhood. This shift in perspective, from fighting the tumor to disrupting its support system, offers a new path forward for patients who have seen their treatments fail.